Auryxia (ferric citrate) tablets, 210 mg , 200-count bottles, RX ONLY, Manufactured for and distr...

FDA Recall #D-0133-2018 — Class III — December 12, 2017

Recall #D-0133-2018 Date: December 12, 2017 Classification: Class III Status: Terminated

Product Description

Auryxia (ferric citrate) tablets, 210 mg , 200-count bottles, RX ONLY, Manufactured for and distributed by: Keryx Biopharmaceticals, Inc. One Marina Park Drive, 12th Floor, Boston, MA 02210 USA. NDC 59922-631-01

Reason for Recall

Presence of Foreign Substance: Reports have been received of damaged StripPax packets containing silica gel desiccant potentially allowing the silica gel granules to make contact with Auryxia tablets in the bottle.

Recalling Firm

Keryx Biopharmaceuticals, Inc. — Boston, MA

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

2,488 200-bottles

Distribution

Distributed nationwide in the USA

Code Information

Lot # AH3842

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated